A Comprehensive Overview of Gaucher Disease Drugs Market Landscape

The global gaucher disease drugs market size is expected to reach USD 2.03 billion by 2030, expanding at a CAGR of 2.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for the development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.

Gaucher disease is a genetic metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme required to degrade glucocerebroside. Excess accumulation of lipids in spleen, liver, kidney, brain, lungs, and bone marrow impedes the normal functioning of the organs.

In spite of being the most prevalent lysosomal storage disorder, Gaucher disease is a rare condition with an average prevalence of 1 in 100,000 individuals. However, certain ethnic races such as Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an average disease prevalence of 1 in 500 individuals.

Currently, type 1 is the most common form of Gaucher disease. This condition is nonneuronopathic in nature, as it does not affect the central nervous system (CNS). Type 1 GD commanded more than 75.0% of the market in 2017. It is estimated to retain its position through 2025. Type 2 and type 3 are not as common as type 1.

On the basis of treatment, enzyme replacement therapy (ERT) was the leading revenue contributor in the market in 2017. The growth of the segment can be attributed to the strong sales of Cerezyme and Vpriv. However, there has been an increase in inclination towards substrate replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly indicated for type 1 and type 3 (to address issues unrelated to the CNS), as replacement enzymes cannot penetrate blood brain barrier. Additionally, there is no effective treatment for type 2.

Get a preview of the latest developments in the Gaucher Disease Drugs Market? Download your FREE sample PDF copy and explore key data and trends. 

Gaucher Disease Drugs Market Report Highlights

• Type 2 is the rarest of the three forms of GD, with an average mortality rate of less than two years

• Enzyme replacement therapy dominated the treatment landscape, headed by Sanofi Genzyme’s Cerezyme. However, GD treatment is witnessing a shift towards substrate replacement therapy

• The U.S. spearheaded the major markets, in terms of sales as well as disease burden. The country will continue to dominate the market through 2030, on account of widening the patient base and easy accessibility to treatments

• Some of the prominent companies operating in the market are Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson

Gaucher Disease Drugs Market Segmentation

Grand View Research has segmented the global gaucher disease drugs market based on type, therapy, and region:

Gaucher Disease Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Type 1

• Type 2

• Type 3

• Others

Gaucher Disease Drugs Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Enzyme Replacement Therapy

• Substrate Replacement Therapy

• Others

Gaucher Disease Drugs Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o U.K.

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o China

o Japan

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

List of Key Players in Gaucher Disease Drugs Market

• Sanofi

• Takeda Pharmaceutical Company Limited

• Pfizer Inc

• Johnson & Johnson Services, Inc.

• ERAD Therapeutic

Order a free sample PDF of the Gaucher Disease Drugs Market Intelligence Study, published by Grand View Research.